Logo image of TMDX

TRANSMEDICS GROUP INC (TMDX) Stock Fundamental Analysis

NASDAQ:TMDX - Nasdaq - US89377M1099 - Common Stock - Currency: USD

115.68  -1.2 (-1.03%)

After market: 115.68 0 (0%)

Fundamental Rating

5

Taking everything into account, TMDX scores 5 out of 10 in our fundamental rating. TMDX was compared to 187 industry peers in the Health Care Equipment & Supplies industry. TMDX has only an average score on both its financial health and profitability. TMDX shows excellent growth, but is valued quite expensive already.


Dividend Valuation Growth Profitability Health

Quickly go to:

4

1. Profitability

1.1 Basic Checks

In the past year TMDX was profitable.
In the past year TMDX had a positive cash flow from operations.
In the past 5 years TMDX reported 4 times negative net income.
TMDX had negative operating cash flow in 4 of the past 5 years.
TMDX Yearly Net Income VS EBIT VS OCF VS FCFTMDX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -50M -100M -150M

1.2 Ratios

Looking at the Return On Assets, with a value of 5.84%, TMDX belongs to the top of the industry, outperforming 86.10% of the companies in the same industry.
With an excellent Return On Equity value of 18.38%, TMDX belongs to the best of the industry, outperforming 92.51% of the companies in the same industry.
Looking at the Return On Invested Capital, with a value of 5.31%, TMDX is in the better half of the industry, outperforming 79.14% of the companies in the same industry.
Industry RankSector Rank
ROA 5.84%
ROE 18.38%
ROIC 5.31%
ROA(3y)-4.07%
ROA(5y)-12.78%
ROE(3y)-7.35%
ROE(5y)-22.97%
ROIC(3y)N/A
ROIC(5y)N/A
TMDX Yearly ROA, ROE, ROICTMDX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100 -100 200 300 400

1.3 Margins

TMDX's Profit Margin of 10.03% is amongst the best of the industry. TMDX outperforms 83.96% of its industry peers.
With a decent Operating Margin value of 10.76%, TMDX is doing good in the industry, outperforming 78.07% of the companies in the same industry.
The Gross Margin of TMDX (59.47%) is comparable to the rest of the industry.
TMDX's Gross Margin has been stable in the last couple of years.
Industry RankSector Rank
OM 10.76%
PM (TTM) 10.03%
GM 59.47%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-5.32%
GM growth 5Y0.21%
TMDX Yearly Profit, Operating, Gross MarginsTMDX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -100 -200 -300

More info and screens

5

2. Health

2.1 Basic Checks

The Return on Invested Capital (ROIC) is below the Cost of Capital (WACC), so TMDX is destroying value.
The number of shares outstanding for TMDX has been increased compared to 1 year ago.
TMDX has more shares outstanding than it did 5 years ago.
TMDX has a better debt/assets ratio than last year.
TMDX Yearly Shares OutstandingTMDX Yearly Shares OutstandingYearly Shares Outstanding 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M
TMDX Yearly Total Debt VS Total AssetsTMDX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M

2.2 Solvency

TMDX has an Altman-Z score of 4.85. This indicates that TMDX is financially healthy and has little risk of bankruptcy at the moment.
TMDX has a better Altman-Z score (4.85) than 76.47% of its industry peers.
A Debt/Equity ratio of 1.92 is on the high side and indicates that TMDX has dependencies on debt financing.
The Debt to Equity ratio of TMDX (1.92) is worse than 85.03% of its industry peers.
Industry RankSector Rank
Debt/Equity 1.92
Debt/FCF N/A
Altman-Z 4.85
ROIC/WACC0.64
WACC8.23%
TMDX Yearly LT Debt VS Equity VS FCFTMDX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M 400M

2.3 Liquidity

TMDX has a Current Ratio of 9.10. This indicates that TMDX is financially healthy and has no problem in meeting its short term obligations.
TMDX's Current ratio of 9.10 is amongst the best of the industry. TMDX outperforms 91.98% of its industry peers.
A Quick Ratio of 8.32 indicates that TMDX has no problem at all paying its short term obligations.
TMDX has a Quick ratio of 8.32. This is amongst the best in the industry. TMDX outperforms 91.98% of its industry peers.
Industry RankSector Rank
Current Ratio 9.1
Quick Ratio 8.32
TMDX Yearly Current Assets VS Current LiabilitesTMDX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M 500M

More info and screens

8

3. Growth

3.1 Past

TMDX shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 500.00%, which is quite impressive.
The Revenue has grown by 64.43% in the past year. This is a very strong growth!
The Revenue has been growing by 79.64% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)500%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%100%
Revenue 1Y (TTM)64.43%
Revenue growth 3Y144.36%
Revenue growth 5Y79.64%
Sales Q2Q%48.21%

3.2 Future

TMDX is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 49.75% yearly.
TMDX is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 21.08% yearly.
EPS Next Y82.44%
EPS Next 2Y59.67%
EPS Next 3Y47.23%
EPS Next 5Y49.75%
Revenue Next Year34.91%
Revenue Next 2Y27.64%
Revenue Next 3Y24.32%
Revenue Next 5Y21.08%

3.3 Evolution

Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
TMDX Yearly Revenue VS EstimatesTMDX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 200M 400M 600M 800M 1B
TMDX Yearly EPS VS EstimatesTMDX Yearly EPS VS EstimatesYearly EPS VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 0 2 -2 4 -4 -6

More info and screens

3

4. Valuation

4.1 Price/Earnings Ratio

Based on the Price/Earnings ratio of 85.06, the valuation of TMDX can be described as expensive.
64.17% of the companies in the same industry are more expensive than TMDX, based on the Price/Earnings ratio.
When comparing the Price/Earnings ratio of TMDX to the average of the S&P500 Index (27.19), we can say TMDX is valued expensively.
Based on the Price/Forward Earnings ratio of 44.93, the valuation of TMDX can be described as expensive.
Compared to the rest of the industry, the Price/Forward Earnings ratio of TMDX indicates a somewhat cheap valuation: TMDX is cheaper than 68.45% of the companies listed in the same industry.
TMDX is valuated rather expensively when we compare the Price/Forward Earnings ratio to 35.33, which is the current average of the S&P500 Index.
Industry RankSector Rank
PE 85.06
Fwd PE 44.93
TMDX Price Earnings VS Forward Price EarningsTMDX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 20 40 60 80

4.2 Price Multiples

Based on the Enterprise Value to EBITDA ratio, TMDX is valued a bit cheaper than 64.71% of the companies in the same industry.
Industry RankSector Rank
P/FCF N/A
EV/EBITDA 56.05
TMDX Per share dataTMDX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 10

4.3 Compensation for Growth

TMDX's PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a correct valuation of the company.
TMDX's earnings are expected to grow with 47.23% in the coming years. This may justify a more expensive valuation.
PEG (NY)1.03
PEG (5Y)N/A
EPS Next 2Y59.67%
EPS Next 3Y47.23%

More info and screens

0

5. Dividend

5.1 Amount

TMDX does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

TRANSMEDICS GROUP INC

NASDAQ:TMDX (7/15/2025, 5:42:53 PM)

After market: 115.68 0 (0%)

115.68

-1.2 (-1.03%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)05-08 2025-05-08/amc
Earnings (Next)07-31 2025-07-31/amc
Inst Owners121.41%
Inst Owner Change0%
Ins Owners2.98%
Ins Owner Change18.64%
Market Cap3.91B
Analysts81.25
Price Target141.78 (22.56%)
Short Float %24.52%
Short Ratio8.11
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)91.9%
Min EPS beat(2)16.42%
Max EPS beat(2)167.38%
EPS beat(4)3
Avg EPS beat(4)46.83%
Min EPS beat(4)-59.86%
Max EPS beat(4)167.38%
EPS beat(8)6
Avg EPS beat(8)142.41%
EPS beat(12)9
Avg EPS beat(12)105.32%
EPS beat(16)10
Avg EPS beat(16)74.65%
Revenue beat(2)2
Avg Revenue beat(2)10.96%
Min Revenue beat(2)8.12%
Max Revenue beat(2)13.8%
Revenue beat(4)3
Avg Revenue beat(4)6.97%
Min Revenue beat(4)-7.28%
Max Revenue beat(4)13.8%
Revenue beat(8)7
Avg Revenue beat(8)13.88%
Revenue beat(12)11
Avg Revenue beat(12)16.77%
Revenue beat(16)14
Avg Revenue beat(16)17.35%
PT rev (1m)3.73%
PT rev (3m)20.48%
EPS NQ rev (1m)0.12%
EPS NQ rev (3m)23.21%
EPS NY rev (1m)2.53%
EPS NY rev (3m)23.31%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)10.37%
Revenue NY rev (1m)0.02%
Revenue NY rev (3m)6.98%
Valuation
Industry RankSector Rank
PE 85.06
Fwd PE 44.93
P/S 8.02
P/FCF N/A
P/OCF 79.25
P/B 14.7
P/tB 15.49
EV/EBITDA 56.05
EPS(TTM)1.36
EY1.18%
EPS(NY)2.57
Fwd EY2.23%
FCF(TTM)-1.87
FCFYN/A
OCF(TTM)1.46
OCFY1.26%
SpS14.43
BVpS7.87
TBVpS7.47
PEG (NY)1.03
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA 5.84%
ROE 18.38%
ROCE 6.72%
ROIC 5.31%
ROICexc 8.79%
ROICexgc 9.06%
OM 10.76%
PM (TTM) 10.03%
GM 59.47%
FCFM N/A
ROA(3y)-4.07%
ROA(5y)-12.78%
ROE(3y)-7.35%
ROE(5y)-22.97%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-5.32%
GM growth 5Y0.21%
F-Score6
Asset Turnover0.58
Health
Industry RankSector Rank
Debt/Equity 1.92
Debt/FCF N/A
Debt/EBITDA 6.88
Cap/Depr 521.51%
Cap/Sales 23.07%
Interest Coverage 250
Cash Conversion 66.63%
Profit Quality N/A
Current Ratio 9.1
Quick Ratio 8.32
Altman-Z 4.85
F-Score6
WACC8.23%
ROIC/WACC0.64
Cap/Depr(3y)951.97%
Cap/Depr(5y)615.69%
Cap/Sales(3y)34.99%
Cap/Sales(5y)23.68%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)500%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%100%
EPS Next Y82.44%
EPS Next 2Y59.67%
EPS Next 3Y47.23%
EPS Next 5Y49.75%
Revenue 1Y (TTM)64.43%
Revenue growth 3Y144.36%
Revenue growth 5Y79.64%
Sales Q2Q%48.21%
Revenue Next Year34.91%
Revenue Next 2Y27.64%
Revenue Next 3Y24.32%
Revenue Next 5Y21.08%
EBIT growth 1Y529.56%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year231.21%
EBIT Next 3Y84.76%
EBIT Next 5Y66.53%
FCF growth 1Y-34.64%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y236.91%
OCF growth 3YN/A
OCF growth 5YN/A